We classified ESCC subjects into four subgroups based on CD3+ TIL positivity and ICOS expression, and the same method was applied for CD3 with PD-1 and CD3 with TIM-3, as these were proposed to have a prognostic impact in the current analysis. This evidence concerns the gene ICOS and esophageal squamous cell carcinoma.